Belpointe Asset Management LLC Grows Stock Holdings in Bristol Myers Squibb Company $BMY

Belpointe Asset Management LLC grew its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY) by 15.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 119,636 shares of the biopharmaceutical company’s stock after buying an additional 16,388 shares during the quarter. Belpointe Asset Management LLC’s holdings in Bristol Myers Squibb were worth $6,453,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Gateway Investment Advisers LLC grew its stake in Bristol Myers Squibb by 10.0% during the third quarter. Gateway Investment Advisers LLC now owns 113,457 shares of the biopharmaceutical company’s stock worth $5,117,000 after buying an additional 10,284 shares during the period. CWA Asset Management Group LLC grew its stake in Bristol Myers Squibb by 25.9% during the third quarter. CWA Asset Management Group LLC now owns 150,359 shares of the biopharmaceutical company’s stock worth $6,781,000 after buying an additional 30,909 shares during the period. Stephens Inc. AR grew its stake in Bristol Myers Squibb by 13.5% during the third quarter. Stephens Inc. AR now owns 273,343 shares of the biopharmaceutical company’s stock worth $12,328,000 after buying an additional 32,476 shares during the period. Railway Pension Investments Ltd grew its stake in Bristol Myers Squibb by 3.7% during the third quarter. Railway Pension Investments Ltd now owns 1,139,600 shares of the biopharmaceutical company’s stock worth $51,396,000 after buying an additional 40,300 shares during the period. Finally, Phoenix Financial Ltd. grew its stake in Bristol Myers Squibb by 110.1% during the third quarter. Phoenix Financial Ltd. now owns 106,154 shares of the biopharmaceutical company’s stock worth $4,789,000 after buying an additional 55,624 shares during the period. 76.41% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Bristol Myers Squibb news, EVP David V. Elkins sold 30,000 shares of the stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the transaction, the executive vice president directly owned 159,248 shares in the company, valued at $9,820,824.16. This represents a 15.85% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 0.05% of the stock is owned by company insiders.

Bristol Myers Squibb Trading Up 0.1%

NYSE BMY opened at $60.21 on Monday. Bristol Myers Squibb Company has a 12 month low of $42.52 and a 12 month high of $62.89. The company has a debt-to-equity ratio of 2.32, a current ratio of 1.26 and a quick ratio of 1.14. The company has a market capitalization of $122.93 billion, a price-to-earnings ratio of 17.45, a price-to-earnings-growth ratio of 0.17 and a beta of 0.27. The company’s fifty day moving average price is $59.82 and its two-hundred day moving average price is $53.73.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported $1.26 EPS for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). Bristol Myers Squibb had a net margin of 14.64% and a return on equity of 69.65%. The company had revenue of $12.50 billion for the quarter, compared to the consensus estimate of $12.24 billion. During the same quarter last year, the company earned $1.67 earnings per share. The company’s revenue was up 1.3% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, research analysts predict that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 1st. Shareholders of record on Thursday, April 2nd will be paid a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 4.2%. The ex-dividend date is Thursday, April 2nd. Bristol Myers Squibb’s dividend payout ratio is 73.04%.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on BMY shares. Leerink Partners upped their target price on shares of Bristol Myers Squibb from $54.00 to $60.00 and gave the company an “outperform” rating in a research note on Tuesday, January 13th. Wall Street Zen upgraded shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research note on Sunday. Barclays started coverage on shares of Bristol Myers Squibb in a research note on Thursday, February 19th. They issued an “overweight” rating and a $75.00 target price for the company. Wells Fargo & Company restated an “outperform” rating and issued a $60.00 target price (up from $55.00) on shares of Bristol Myers Squibb in a research note on Friday, February 6th. Finally, Piper Sandler restated an “overweight” rating and issued a $75.00 target price (up from $66.00) on shares of Bristol Myers Squibb in a research note on Monday, February 23rd. Nine analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $61.71.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.